Amyloid Transthyretin (ATTR) Learning Center
This Amyloid Transthyretin (ATTR) Learning Center is developed by key opinion leaders in the fields of cardiology and neurology to educate healthcare providers on ATTR, a progressive, multisystemic disease that is often misdiagnosed due to a lack of familiarity with its clinical manifestations. Explore the latest advancements, mechanisms of action, and clinical applications of multiple therapies designed to care for patients with ATTR. Our mission is to turbocharge healthcare providers’ clinical proficiency, empowering them to skillfully navigate the nuances of ATTR within a comprehensive educational environment. Prepare to elevate your understanding of ATTR and impact patient care – because the future of ATTR education starts here.
1-7 of 7

The Clinical Weight of TTR: What the Latest Data Reveal
CME/CEThe Clinical Weight of TTR: What the Latest Data Reveal

Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
CME/CELatest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction

Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
CME/CEBreaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025

TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
CME/CETTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference

AHA 2024 and Acoramidis: Impact on the Future of ATTR-CM Patient Care
CME/CEAHA 2024 and Acoramidis: Impact on the Future of ATTR-CM Patient Care

The Shifting ATTR-CM Landscape: Early Diagnosis, Emerging Therapies & Personalized Care
CME/CEThe Shifting ATTR-CM Landscape: Early Diagnosis, Emerging Therapies & Personalized Care
- advertisement

Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice
CME/CEStrategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice


























